175 related articles for article (PubMed ID: 15326914)
1. Physicochemical determinants for drug induced blockade of HERG potassium channels: effect of charge and charge shielding.
Zolotoy AB; Plouvier BP; Beatch GB; Hayes ES; Wall RA; Walker MJ
Curr Med Chem Cardiovasc Hematol Agents; 2003 Oct; 1(3):225-41. PubMed ID: 15326914
[TBL] [Abstract][Full Text] [Related]
2. Drug block of I(kr): model systems and relevance to human arrhythmias.
Yang T; Snyders D; Roden DM
J Cardiovasc Pharmacol; 2001 Nov; 38(5):737-44. PubMed ID: 11602820
[TBL] [Abstract][Full Text] [Related]
3. IKr channel blockers: novel antiarrhythmic agents.
Lee K; Park JY; Ryu PD; Kwon LS; Kim HY
Curr Med Chem Cardiovasc Hematol Agents; 2003 Oct; 1(3):203-23. PubMed ID: 15326913
[TBL] [Abstract][Full Text] [Related]
4. Comparative pharmacology of guinea pig cardiac myocyte and cloned hERG (I(Kr)) channel.
Davie C; Pierre-Valentin J; Pollard C; Standen N; Mitcheson J; Alexander P; Thong B
J Cardiovasc Electrophysiol; 2004 Nov; 15(11):1302-9. PubMed ID: 15574182
[TBL] [Abstract][Full Text] [Related]
5. Testosterone-mediated modulation of HERG blockade by proarrhythmic agents.
Shuba YM; Degtiar VE; Osipenko VN; Naidenov VG; Woosley RL
Biochem Pharmacol; 2001 Jul; 62(1):41-9. PubMed ID: 11377395
[TBL] [Abstract][Full Text] [Related]
6. A mechanism for the proarrhythmic effects of cisapride (Propulsid): high affinity blockade of the human cardiac potassium channel HERG.
Rampe D; Roy ML; Dennis A; Brown AM
FEBS Lett; 1997 Nov; 417(1):28-32. PubMed ID: 9395068
[TBL] [Abstract][Full Text] [Related]
7. Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development.
Redfern WS; Carlsson L; Davis AS; Lynch WG; MacKenzie I; Palethorpe S; Siegl PK; Strang I; Sullivan AT; Wallis R; Camm AJ; Hammond TG
Cardiovasc Res; 2003 Apr; 58(1):32-45. PubMed ID: 12667944
[TBL] [Abstract][Full Text] [Related]
8. Blockade of HERG channels by the class III antiarrhythmic azimilide: mode of action.
Busch AE; Eigenberger B; Jurkiewicz NK; Salata JJ; Pica A; Suessbrich H; Lang F
Br J Pharmacol; 1998 Jan; 123(1):23-30. PubMed ID: 9484850
[TBL] [Abstract][Full Text] [Related]
9. Human ether-a-go-go-related gene channel blockers and its structural analysis for drug design.
Narayana Moorthy NS; Ramos MJ; Fernandes PA
Curr Drug Targets; 2013 Jan; 14(1):102-13. PubMed ID: 23061466
[TBL] [Abstract][Full Text] [Related]
10. Mechanism of block and identification of the verapamil binding domain to HERG potassium channels.
Zhang S; Zhou Z; Gong Q; Makielski JC; January CT
Circ Res; 1999 May; 84(9):989-98. PubMed ID: 10325236
[TBL] [Abstract][Full Text] [Related]
11. I(Kr): the hERG channel.
Tseng GN
J Mol Cell Cardiol; 2001 May; 33(5):835-49. PubMed ID: 11343409
[TBL] [Abstract][Full Text] [Related]
12. Class III antiarrhythmic drugs block HERG, a human cardiac delayed rectifier K+ channel. Open-channel block by methanesulfonanilides.
Spector PS; Curran ME; Keating MT; Sanguinetti MC
Circ Res; 1996 Mar; 78(3):499-503. PubMed ID: 8593709
[TBL] [Abstract][Full Text] [Related]
13. Molecular determinants of inactivation and dofetilide block in ether a-go-go (EAG) channels and EAG-related K(+) channels.
Ficker E; Jarolimek W; Brown AM
Mol Pharmacol; 2001 Dec; 60(6):1343-8. PubMed ID: 11723241
[TBL] [Abstract][Full Text] [Related]
14. Electrophysiological and antiarrhythmic effects of the novel I(Kur) channel blockers, S9947 and S20951, on left vs. right pig atrium in vivo in comparison with the I(Kr) blockers dofetilide, azimilide, d,l-sotalol and ibutilide.
Knobloch K; Brendel J; Peukert S; Rosenstein B; Busch AE; Wirth KJ
Naunyn Schmiedebergs Arch Pharmacol; 2002 Nov; 366(5):482-7. PubMed ID: 12382079
[TBL] [Abstract][Full Text] [Related]
15. Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG.
Kang J; Wang L; Chen XL; Triggle DJ; Rampe D
Mol Pharmacol; 2001 Jan; 59(1):122-6. PubMed ID: 11125032
[TBL] [Abstract][Full Text] [Related]
16. High-affinity blockade of human ether-a-go-go-related gene human cardiac potassium channels by the novel antiarrhythmic drug BRL-32872.
Thomas D; Wendt-Nordahl G; Röckl K; Ficker E; Brown AM; Kiehn J
J Pharmacol Exp Ther; 2001 May; 297(2):753-61. PubMed ID: 11303067
[TBL] [Abstract][Full Text] [Related]
17. Modulation of HERG potassium channels by extracellular magnesium and quinidine.
Po SS; Wang DW; Yang IC; Johnson JP; Nie L; Bennett PB
J Cardiovasc Pharmacol; 1999 Feb; 33(2):181-5. PubMed ID: 10028924
[TBL] [Abstract][Full Text] [Related]
18. Acidification alters antiarrhythmic drug blockade of the ether-a-go-go-related Gene (HERG) Channels.
Dong DL; Li Z; Wang HZ; Du ZM; Song WH; Yang BF
Basic Clin Pharmacol Toxicol; 2004 May; 94(5):209-12. PubMed ID: 15125690
[TBL] [Abstract][Full Text] [Related]
19. Blockade of HERG potassium currents by fluvoxamine: incomplete attenuation by S6 mutations at F656 or Y652.
Milnes JT; Crociani O; Arcangeli A; Hancox JC; Witchel HJ
Br J Pharmacol; 2003 Jul; 139(5):887-98. PubMed ID: 12839862
[TBL] [Abstract][Full Text] [Related]
20. The cardiac hERG/IKr potassium channel as pharmacological target: structure, function, regulation, and clinical applications.
Thomas D; Karle CA; Kiehn J
Curr Pharm Des; 2006; 12(18):2271-83. PubMed ID: 16787254
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
